"Advancing our pipeline efficiently remains our top priority as we leverage our innovative capabilities in the HAE sector." - Andrew McDade, CEO
— Andrew McDade
03Detailed Report
KALV
KalVista Pharmaceuticals Inc
Period
Q3 2024
CurrencyUSD
Report TypeQuarterly Earnings
GeneratedJun 28, 2026
Swipe to view all report sections
Executive Summary
KalVista Pharmaceuticals Inc (KALV) reported a net loss of approximately $29 million for Q3 2024, reflecting continued challenges in translating its research and development efforts into commercial success. The company's key products are in various stages of clinical trials, particularly focusing on plasma kallikrein inhibitors for hereditary angioedema (HAE) and diabetic macular edema (DME).
Management signaled a committed focus on advancing clinical trials, particularly the Phase 3 KONFIDENT trial for sebetralstat, a potential on-demand therapy for HAE. While no revenues were reported this quarter, KalVista maintained a robust cash position of $23 million, supported by substantial investment in R&D amounting to $22.5 million, showcasing a focus on innovation despite ongoing operational losses.
Key Performance Indicators
Operating Income
Decreasing
-33.15M
QoQ: -11.45% | YoY: -23.03%
Net Income
Decreasing
-29.03M
QoQ: -4.98% | YoY: -102.54%
EPS
Decreasing
-0.84
QoQ: -5.00% | YoY: -64.71%
Revenue Trend
Margin Analysis
Financial Highlights
### Financial Performance Overview
- Revenue: $0, with significant investment into R&D.
- Net Income: -$29.0 million, translating to an EPS of -$0.84, reflecting a 102.54% decline year-over-year (YoY) and a marginal 4.98% decrease quarter-over-quarter (QoQ).
- Operating Income: -$33.15 million, an 11.45% reduction from the previous quarter, signaling increasing operational inefficiencies.
- Total Operating Expenses: $33.15 million, comprised of R&D ($22.5 million) and general administrative expenses ($10.6 million).
### Ratio Analysis
- Current Ratio: 5.44, indicating a strong liquidity position, far exceeding the industry average.
- Return on Equity (ROE): -32.8%, indicating the firm’s difficulties in generating income.
Income Statement
Metric
Value
YoY Change
QoQ Change
Gross Profit
-207.00K
0.96%
-5.08%
Operating Income
-33.15M
-23.03%
-11.45%
Net Income
-29.03M
-102.54%
-4.98%
EPS
-0.84
-64.71%
-5.00%
Key Financial Ratios
Return on Assets
Weak
-0.26%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
-0.33%
Return on equity suggests inefficient capital allocation
Current Ratio
Strong
5.44
Current ratio indicates excellent liquidity and financial flexibility
Debt to Equity
Conservative
0.08
Debt-to-equity shows conservative leverage and low financial risk
P/E Ratio
Negative
-4.72x
Negative earnings make P/E ratio not meaningful
Price to Book
High Premium
6.18x
Very high premium suggests asset-light business model or lofty expectations
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.
KalVista Pharmaceuticals Inc (KALV) QQ1 2026 Results Analysis — Early US Launch of EKTERLY Drives Modest Revenue but Funds Global Commercial Expansi...